These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23717383)

  • 41. Association between systemic activity ındex and dry eye severity in patients with primary Sjögren syndrome.
    Ozek D; Kemer OE; Omma A
    Arq Bras Oftalmol; 2019; 82(1):45-50. PubMed ID: 30403265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
    Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pulmonary involvement in primary Sjögren's syndrome, as measured by the ESSDAI.
    Heus A; Arends S; Van Nimwegen JF; Stel AJ; Nossent GD; Bootsma H
    Scand J Rheumatol; 2020 Jan; 49(1):38-46. PubMed ID: 31556344
    [No Abstract]   [Full Text] [Related]  

  • 44. Elevation of serum soluble intercellular adhesion molecule-1 (sICAM-1) and beta-2-microglobulin in Sjögren's syndrome.
    Krejsek J; Slezák R; Kopecky O; Derner V; Andrys C
    Clin Rheumatol; 1997 Mar; 16(2):149-53. PubMed ID: 9093796
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
    Dörner T; Posch MG; Li Y; Petricoul O; Cabanski M; Milojevic JM; Kamphausen E; Valentin MA; Simonett C; Mooney L; Hüser A; Gram H; Wagner FD; Oliver SJ
    Ann Rheum Dis; 2019 May; 78(5):641-647. PubMed ID: 30826774
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IL-14α as a Putative Biomarker for Stratification of Dry Eye in Primary Sjögren's Syndrome.
    Liang Y; Xian Z; Fu D; Liu S; Yao Y; Jin Y; Gao C; Shen L; Shi G; He J
    Front Immunol; 2021; 12():673658. PubMed ID: 34012457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
    Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
    Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beta2 microglobulin and lymphocytic infiltration in Sjögren's syndrome.
    Michalski JP; Daniels TE; Talal N; Grey HM
    N Engl J Med; 1975 Dec; 293(24):1228-31. PubMed ID: 52841
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
    Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
    J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated expression of BAFF receptor, BR3, on monocytes correlates with B cell activation and clinical features of patients with primary Sjögren's syndrome.
    Yoshimoto K; Suzuki K; Takei E; Ikeda Y; Takeuchi T
    Arthritis Res Ther; 2020 Jun; 22(1):157. PubMed ID: 32576236
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
    Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
    Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-carbonic anhydrase autoantibodies and serum beta-2 microglobulin correlate with the ClinESSDAI score in patients with Sjögren's syndrome.
    Pertovaara M; Parkkila S; Korpela M
    Clin Exp Rheumatol; 2017; 35(2):351. PubMed ID: 28079504
    [No Abstract]   [Full Text] [Related]  

  • 55. Association of BAFF and IL-17A with subphenotypes of primary Sjögren's syndrome.
    Deng F; Chen J; Zheng J; Chen Y; Huang R; Yin J; Gao X; Lin Q; Huang C; Gao Y; Yu X; Liu Z
    Int J Rheum Dis; 2016 Jul; 19(7):715-20. PubMed ID: 25941062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elevated levels of faecal calprotectin in primary Sjögren's syndrome is common and associated with concomitant organic gastrointestinal disease.
    Andréasson K; Ohlsson B; Mandl T
    Arthritis Res Ther; 2016 Jan; 18():9. PubMed ID: 26759247
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progenitor cell niche senescence reflects pathology of the parotid salivary gland in primary Sjögren's syndrome.
    Wang X; Bootsma H; Terpstra J; Vissink A; van der Vegt B; Spijkervet FKL; Kroese FGM; Pringle S
    Rheumatology (Oxford); 2020 Oct; 59(10):3003-3013. PubMed ID: 32159757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum beta-2-microglobulin in Sjögren's syndrome.
    Ström T; Evrin PE; Karlsson A
    Scand J Rheumatol; 1978; 7(2):97-100. PubMed ID: 81519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.
    Sellam J; Miceli-Richard C; Gottenberg JE; Ittah M; Lavie F; Lacabaratz C; Gestermann N; Proust A; Lambotte O; Mariette X
    Ann Rheum Dis; 2007 Jun; 66(6):790-7. PubMed ID: 17185325
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polyarthritis in primary Sjögren's syndrome represents a distinct subset with less pronounced B cell proliferation a Dutch cohort with long-term follow-up.
    ter Borg EJ; Kelder JC
    Clin Rheumatol; 2016 Mar; 35(3):649-55. PubMed ID: 26791875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.